“Meet the Latest CEO Price Gouging on Life-Saving Medications”

The following exposes what most of we the individuals will be facing after the TPP becomes ‘reality’:

Meet the Latest CEO Price Gouging on Life-Saving Medications

By Justin Gardner

Editor’s Note: Again, it’s debatable whether or not these medications are truly “life-saving” vs. alternative solutions, but this story is another illustration of just how corrupt and lacking in compassion the Big Pharma system really is. So, even if one buys into the need for their products, it is good to know the true face of your soulless supplier.

The Internet may have experienced its biggest outrage ever last month, when pharma bro Martin Shkreli acquired exclusive rights to sell the drug Daraprim and proceeded to raise the price 5,000 percent. This is a life-saving medication for AIDS patients and cancer survivors undergoing chemotherapy, as it prevents infections in people with weakened immune systems.

Being absent of decency and suffused with greed is a way of life in the government-backed Wall St. industry. Valeant Pharmaceuticals CEO Michael Pearson is the latest to demonstrate this.

Rather than focusing on one drug as Shkreli did, the Wall St. darling is jacking up prices for a number of critical brand-name drugs. So far in 2015, Valeant raised prices an average of 66 percent, which is five times as much as its closest industry peers.

Valeant quadrupled the price of Cuprimine overnight, a decades-old drug that treats an inherited disorder called Wilson disease. For one retired carpenter, whose life depends on the drug, it means that he will have to pay $1,800 out of pocket per month, instead of the $366 he used to pay.

Valeant raised the price of Glumetza, a diabetes drug, 800 percent after acquiring the rights this year. Isuprel, which treats heart conditions, now costs eight times what it did last year. Mephyton, which helps blood clotting, went from $9.37 a tablet to $58.75. Edecrin, which treats kidney and liver disease, went from $470 a vial to $4,600.

The company is not interested in research and development of new drugs, as are conventional pharmaceutical companies. Valeant just buys up existing drug companies and jacks up prices wherever possible, focusing mostly on older drugs that still have patent protection or have no generic competition.

It is important to note that making a profit is not the issue at hand with the pharmaceutical companies hiking prices. The issue is that the prices are able to be hiked to such extremes because of government programs which grant these drug makers monopolies in their fields. Pharmaceutical companies use the force of the State to legislate their potential competition out of the market, thereby creating huge windfalls for themselves.

Valeant says it has everyone’s best interests at heart, stating that it “prices its treatments based on a range of factors, including clinical benefits and the value they bring to patients, physicians, payers, and society.”

Pearson says when “products are sort of mispriced and there’s an opportunity, we will act appropriately in terms of doing what I assume our shareholders would like us to do.”

They rely on the justification that patients will be shielded from skyrocketing expenses by insurance companies and government programs, displaying a willful ignorance of the bigger picture.

But even if patients are often shielded, the costs are paid by insurers, hospitals and taxpayers and lead to higher premiums and co-payments for everyone, critics say.

Jeffrey M. Rosner, the senior director for pharmacy sourcing and purchasing at the Cleveland Clinic, said that nine drugs with particularly egregious price increases had cost the hospital an additional $11.2 million annually, an increase of about 10 percent in drug costs for hospitalized patients. And Valeant’s products represented 80 percent of that additional cost, he said.

Valeant’s actions amount to a raping of the system, burrowing into every crevice to squeeze out profit before the parts of the system can adjust. For instance, when Valeant jacks up the price of a drug, it could stimulate generic alternatives, but they would take years to get approved by the Food and Drug Administration… (emphasis added)

Read More Here:

Source: Meet the Latest CEO Price Gouging on Life-Saving Medications

How can I put this gently?

To hell with the “Stockholders!” To hell with Wall Street! And to hell with Pig Pharma, the FDA, CDC, the AMA and this system of government! These creatures, corporations and government agencies are set on destroying the largest portion of humanity for the sake of their insane pursuit of wealth and power!

How long are we the individuals going to put up with this kind of brazen insanity/criminality? How long will it be before we finally have enough guts to stand up to this menace and put an end to it?

2 thoughts on ““Meet the Latest CEO Price Gouging on Life-Saving Medications”

  1. More people need to start refusing chemotherapy: http://www.dailymail.co.uk/health/article-3173307/Does-end-life-chemotherapy-harm-good-New-study-finds-gruelling-treatment-cancer-patients-WORSE-quality-life-going-without.html

    As for AIDS, there are already lots of antiretroviral drugs to choose from that are totally effective in reducing the viral load. People with undetectable levels of HIV in their blood don’t experience opportunistic infections – so I’m not sure I see the need to introduce a new, fantastically expensive drug.

    Liked by 1 person

  2. I agree! I know of the awful effects of chemo on the body through family members’ experiences. I know if I were to ever contract cancer, which my mother’s side is riddled with, they will not use me as a chemical dump!

    I’ll just find a way to get to Oregon!


Comments are closed.